← Eichor
Study identifier: NCT06279130 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Condition: Resectable MMR-deficient Solid Tumors · Resectable MMR-proficient Solid Tumors  ·  Sponsor: The Netherlands Cancer Institute

PhasePhase 2/Phase 3
Planned participants133
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

This description comes directly from the study's public registry record.

Talk to the study team

Marieke van de Belt, MsC  ·  0205129111  ·  m.vd.belt@nki.nl

Always discuss trial participation with your own doctor first.

Locations (1)

The Netherlands Cancer InstituteAmsterdam, North Holland, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06279130